Adaptor protein-2 associated kinase 1 (AAK1) is key in clathrin-mediated endocytosis, which diverse viruses hijack in order to infect cells. Inhibiting AAK1 has been shown to block the entry of hepatitis C, dengue and rabies viruses into cells.
Eilean Therapeutics LLC has presented in vivo data for its first-in-class MALT1 degrader, TE-205, as a disease-modifying therapy for ulcerative colitis.
Montse Rosa Therapeutics Inc. has developed a molecular glue degrader named MRT-2359 that selectively degrades the translation termination factor ERF3A.
Researchers at Crossbridge Bio Inc. have conducted preclinical evaluation of CBB-120, a novel TROP2-directed dual-payload ADC designed to combine TOP1i and ATR inhibitor (ATRi) mechanisms for enhanced therapeutic efficacy.
A collaborative effort is trying to construct the cell atlas of the developing brains of humans and animal models. Using advanced single-cell and spatial technologies, they mapped how brain cell types emerge, diversify and organize over time, offering new insights into the origins of neurodevelopmental and psychiatric conditions. These breakthroughs in genomics and imaging will allow scientists to study complex developmental processes with high resolution.
Transthera Sciences Inc. is out-licensing one of its preclinical NLRP3 inhibitors to Neurocrine Biosciences Inc. under a collaboration agreement worth $881.5 million. Under deal terms, Nanjing, China-based Transthera will receive an undisclosed up-front payment and is eligible to receive research and development and sales-based milestone payments up to $881.5 million.
Haisco Pharmaceutical Group Co. Ltd. has divulged cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of inflammatory, renal, psychiatric, cardiovascular, eye, respiratory and metabolic disorders, as well as cancer.
RSS
